May 7 Shares of Regeneron Pharmaceuticals Inc
, which tumbled 32 percent in 2016, are poised for a
rebound, the financial newspaper Barron's said.
A better-than-expected launch of Regeneron's skin treatment
Dupixent caused shares to soar last week, the paper reported in
its May 8 edition. If Dupixent usage grows faster than expected,
it could take pressure off Regeneron's other drugs, including
eye drug Eylea, Barron's said.
Regeneron said that 900 prescriptions had been written for
Dupixent and that the number of doctors prescribing the drug had
jumped by nearly 50 percent.
(Reporting by Olivia Oran; Editing by Phil Berlowitz)